Neumora Therapeutics (NMRA) Set to Announce Quarterly Earnings on Tuesday

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) is scheduled to announce its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). On average, analysts expect Neumora Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Neumora Therapeutics Trading Up 1.7 %

NASDAQ NMRA traded up $0.20 during midday trading on Tuesday, hitting $11.91. The company had a trading volume of 1,421,880 shares, compared to its average volume of 712,174. The company has a market capitalization of $1.91 billion, a PE ratio of -4.65 and a beta of 3.92. The firm has a 50-day moving average price of $12.92 and a 200-day moving average price of $11.30. Neumora Therapeutics has a twelve month low of $8.33 and a twelve month high of $21.00.

Insider Buying and Selling

In other Neumora Therapeutics news, insider Robert A. Lenz sold 5,563 shares of the company's stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total value of $83,500.63. Following the sale, the insider now owns 322,966 shares in the company, valued at approximately $4,847,719.66. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, insider Robert A. Lenz sold 5,563 shares of the business's stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total value of $83,500.63. Following the transaction, the insider now directly owns 322,966 shares of the company's stock, valued at $4,847,719.66. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Robert A. Lenz sold 30,788 shares of the company's stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the transaction, the insider now directly owns 339,205 shares in the company, valued at approximately $4,006,011.05. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 110,538 shares of company stock worth $1,390,513 in the last 90 days. Insiders own 26.40% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on NMRA shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a report on Friday, October 18th. JPMorgan Chase & Co. cut Neumora Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $18.00 to $15.00 in a report on Tuesday. HC Wainwright assumed coverage on Neumora Therapeutics in a research note on Tuesday, October 1st. They issued a "buy" rating and a $30.00 price target on the stock. Royal Bank of Canada reiterated an "outperform" rating and issued a $29.00 price target on shares of Neumora Therapeutics in a research note on Wednesday, September 4th. Finally, Mizuho assumed coverage on Neumora Therapeutics in a research note on Monday, July 8th. They issued an "outperform" rating and a $20.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Neumora Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.67.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.